GSK Arexvy vs Pfizer Abrysvo RSV Vaccine — PatSnap Eureka
GSK Arexvy vs Pfizer Abrysvo: RSV Vaccine Competitive Dynamics
The adult RSV vaccine market is a defining competitive battleground. Arexvy's adjuvanted platform and Abrysvo's bivalent approach are diverging across IP, clinical expansion, and combination vaccine strategy — with ages 18–49 as the next frontier.
Two Prefusion F Platforms, Two Distinct IP Strategies
Both GSK Arexvy and Pfizer Abrysvo are built on prefusion F protein antigen technology, but their divergence in adjuvant strategy, formulation IP, and pipeline ambition defines the competitive landscape in RSV immunization.
Adjuvanted Prefusion F: The AS01E Advantage
Arexvy pairs a recombinant prefusion F protein antigen with GSK's proprietary AS01E adjuvant system. This combination is designed to amplify immune response, and the AS01E formulation itself represents a distinct and separately protectable IP layer beyond the antigen. Assignee filings from GlaxoSmithKline Biologicals cover both the antigen stabilization approach and the adjuvant composition — creating a layered patent estate that competitors must navigate.
AS01E adjuvant formulation IPBivalent Non-Adjuvanted: Antigen Breadth as Differentiation
Abrysvo is a bivalent, non-adjuvanted formulation combining two prefusion F protein variants targeting RSV-A and RSV-B subtypes. Pfizer's IP strategy centres on the bivalent antigen composition and stabilization engineering, without the additional adjuvant IP layer. This approach simplifies manufacturing complexity while leveraging dual-subtype coverage as a clinical and regulatory differentiator in populations tracked by public health authorities.
Bivalent RSV-A + RSV-B coveragePrefusion F Protein Stabilization: The Common Core
Both vaccines share a fundamental technological foundation: stabilization of the RSV F protein in its prefusion conformation, which presents the neutralization-sensitive site Ø epitope. Patent filings in this space — from both GSK and Pfizer, as well as academic institutions — cover the structural engineering approaches that lock the F protein in its pre-fusion state. This shared antigen basis means the competitive differentiation must be built on top of this common platform through adjuvant, formulation, and indication strategy.
Prefusion F site Ø epitope targetingFirst Approvals for Adults 60+ — Now Expanding to 18–49
Both Arexvy and Abrysvo achieved regulatory approval for adults aged 60 and older, marking the first RSV vaccines for this population. The next competitive frontier is label expansion to adults aged 18–49, particularly immunocompromised individuals and pregnant populations. Clinical trial activity in these cohorts — tracked by registries monitored by NIH-affiliated researchers — represents the key next phase of the RSV vaccine race.
Ages 18–49 label expansion targetThree Search Dimensions for RSV Vaccine Competitive Intelligence
Recommended query strategies across mechanism, clinical, and combination vaccine dimensions — each representing a distinct layer of the RSV competitive landscape.
RSV Vaccine IP Search Dimensions by Strategic Priority
Three recommended search dimensions — Mechanism/IP, Clinical/Translational, and Combination Vaccine — each covering distinct patent and literature signals.
RSV Vaccine IP Layer Composition: Arexvy vs Abrysvo
Arexvy's IP estate spans three distinct layers; Abrysvo's centres on two — reflecting the adjuvant vs. bivalent antigen differentiation strategies.
How to Query the RSV Vaccine Patent Landscape
Analysts seeking comprehensive RSV vaccine competitive intelligence should approach the patent and literature database across three distinct dimensions, each designed to surface a different layer of the competitive landscape. This methodology is recommended for any future retrieval attempt targeting patent landscape analysis in this space.
The Mechanism and IP Dimension targets the core technological foundation: prefusion F protein stabilization patents, AS01E adjuvant formulation filings, and RSV subunit vaccine composition claims. Queries should be filtered to assignees GlaxoSmithKline Biologicals and Pfizer Inc. to isolate company-specific IP strategy signals from the broader academic and institutional filing activity tracked by EPO patent databases.
The Clinical and Translational Dimension queries Phase III RSV vaccine trials in adults aged 18–49, immunocompromised populations, and pregnancy indications. This requires combining clinical trial registry sources with PubMed-indexed publications to capture both registered trial activity and published immunogenicity data. Life sciences intelligence platforms that integrate both patent and literature sources provide the most complete view.
The Combination Vaccine Dimension targets RSV plus influenza or RSV plus COVID-19 combination vaccine filings and comparative immunogenicity publications from 2022 to 2025. This emerging competitive dimension extends the analysis beyond standalone RSV vaccine approvals and into the broader respiratory immunization portfolio strategies of both companies.
Key Strategic Signals in the RSV Vaccine Race
Four dimensions where GSK and Pfizer are diverging — and where patent and literature analysis can surface actionable intelligence.
Adjuvant IP as a Moat
GSK's AS01E adjuvant system is a proprietary formulation that adds a distinct IP protection layer beyond the prefusion F antigen. Formulation filings in this space represent a moat that competitors must navigate independently of the antigen stabilization patents — making Arexvy's IP estate structurally deeper than Abrysvo's two-layer approach.
Bivalent Subtype Coverage as Differentiation
Pfizer's bivalent RSV-A and RSV-B formulation strategy positions Abrysvo as a broader-spectrum option without the manufacturing complexity of an adjuvant system. This approach concentrates IP protection on the antigen composition and stabilization engineering, rather than the immunological amplification mechanism used by Arexvy.
Arexvy vs Abrysvo: Platform Attributes at a Glance
A structured comparison of the two leading RSV vaccine platforms across key technical, IP, and strategic dimensions relevant to competitive intelligence analysis.
| Dimension | GSK Arexvy | Pfizer Abrysvo |
|---|---|---|
| Antigen Platform | Prefusion F protein (recombinant)Shared | Prefusion F protein (bivalent RSV-A + RSV-B)Shared |
| Adjuvant | AS01E (proprietary)IP Advantage | None (non-adjuvanted) |
| Subtype Coverage | RSV-A and RSV-B | Bivalent RSV-A + RSV-B (explicit)Differentiated |
| IP Layer Depth | 3 layers (antigen, adjuvant, combination) | 2 layers (antigen composition, combination) |
| Initial Approval Population | Adults 60+ | Adults 60+ |
| Expansion Target | Ages 18–49 (immunocompromised, pregnancy) | Ages 18–49 (immunocompromised, pregnancy) |
| Combination Pipeline | RSV + influenza; RSV + COVID-19 filings | RSV + influenza; RSV + COVID-19 filings |
| Manufacturing Complexity | Higher (adjuvant formulation step) | Lower (no adjuvant system required) |
Query Full Assignee-Level IP Activity for Both Platforms
PatSnap Eureka searches GlaxoSmithKline Biologicals and Pfizer Inc. patent estates across all RSV vaccine dimensions simultaneously.
GSK Arexvy vs Pfizer Abrysvo RSV Vaccine — key questions answered
Both GSK Arexvy and Pfizer Abrysvo are prefusion F protein-based RSV vaccines approved for older adults. Arexvy uses GSK's AS01E adjuvant system, while Abrysvo is a non-adjuvanted bivalent formulation. These platform differences drive distinct immunogenicity profiles and are central to ongoing competitive differentiation as both companies pursue label expansion into younger at-risk populations aged 18–49.
Beyond the initial approvals for adults aged 60 and older, both GSK and Pfizer are pursuing label expansion into adults aged 18–49, including immunocompromised individuals and pregnant populations. Clinical trial activity in these cohorts represents a key next phase of the RSV vaccine competitive landscape.
The most strategically significant IP dimensions include prefusion F protein stabilization patents, AS01E adjuvant formulation filings, RSV subunit vaccine composition claims, and combination vaccine filings pairing RSV with influenza or COVID-19 antigens. Assignee-level activity from GlaxoSmithKline Biologicals and Pfizer Inc. across these dimensions signals each company's future pipeline direction.
GSK's AS01E adjuvant system is a proprietary formulation designed to enhance immune response to the prefusion F antigen. Its inclusion differentiates Arexvy from Abrysvo's non-adjuvanted approach and is a central element of GSK's IP strategy, with formulation filings representing a distinct layer of patent protection beyond the antigen itself.
Both companies are exploring RSV combination vaccine opportunities, including RSV plus influenza and RSV plus COVID-19 antigen combinations. Patent filings from 2022–2025 in this space represent an emerging competitive dimension that extends beyond standalone RSV vaccine approvals and into broader respiratory immunization portfolios.
PatSnap Eureka provides AI-powered search across patent and scientific literature databases, enabling analysts to query prefusion F protein stabilization patents, adjuvant formulation filings, assignee-specific IP activity for GSK and Pfizer, and clinical translational signals from trial registries and PubMed-indexed publications — all within a single intelligence platform.
Still have questions? Let PatSnap Eureka search the RSV patent and literature landscape for you.
Ask Eureka About RSV VaccinesMap the RSV Vaccine IP Landscape with AI-Powered Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D and competitive intelligence workflows.
References
- World Health Organization (WHO) — RSV and adult immunization resources
- Centers for Disease Control and Prevention (CDC) — RSV vaccine guidance and public health tracking
- National Institutes of Health (NIH) — RSV clinical trial registry and research publications
- European Patent Office (EPO) — Patent database for RSV vaccine assignee filings
- PatSnap — Innovation intelligence platform and patent analytics
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Platform and IP signal analysis is derived from PatSnap Eureka patent and literature database query methodology. This page represents a structured intelligence framework and should not be interpreted as a comprehensive clinical or regulatory review.
PatSnap Eureka searches patents and research to answer instantly.